247 related articles for article (PubMed ID: 31227223)
1. PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors.
Tang M; O'Connell RL; Amant F; Beale P; McNally O; Sjoquist KM; Grant P; Davis A; Sykes P; Mileshkin L; Moujaber T; Kennedy CJ; deFazio A; Tan K; Antill Y; Goh J; Bonaventura T; Scurry J; Friedlander M
Gynecol Oncol; 2019 Sep; 154(3):531-538. PubMed ID: 31227223
[TBL] [Abstract][Full Text] [Related]
2. PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression.
Kok PS; Beale P; O'Connell RL; Grant P; Bonaventura T; Scurry J; Antill Y; Goh J; Sjoquist K; DeFazio A; Mapagu C; Amant F; Friedlander M;
J Gynecol Oncol; 2019 Sep; 30(5):e86. PubMed ID: 31328463
[TBL] [Abstract][Full Text] [Related]
3. Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer.
Bonaventura A; OʼConnell RL; Mapagu C; Beale PJ; McNally OM; Mileshkin LR; Grant PT; Hadley AM; Goh JCH; Sjoquist KM; Martyn J; DeFazio A; Scurry J; Friedlander ML;
Int J Gynecol Cancer; 2017 Jun; 27(5):900-906. PubMed ID: 28498256
[TBL] [Abstract][Full Text] [Related]
4. A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial.
Banerjee SN; Tang M; O'Connell RL; Sjoquist K; Clamp AR; Millan D; Nottley S; Lord R; Mullassery VM; Hall M; Gourley C; Bonaventura T; Goh JC; Sykes P; Grant PT; McNally O; Alexander L; Kelly C; Carty K; Divers L; Bradshaw N; Edmondson RJ; Friedlander M;
Gynecol Oncol; 2021 Oct; 163(1):72-78. PubMed ID: 34412908
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903).
Friedlander M; Benson C; O'Connell RL; Reed N; Clamp A; Lord R; Millan D; Nottley S; Amant F; Steer C; Anand A; Mileshkin L; Beale P; Banerjee S; Bradshaw N; Kelly C; Carty K; Divers L; Alexander L; Edmondson R
Gynecol Oncol; 2021 Apr; 161(1):160-165. PubMed ID: 33608144
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903).
Edmondson RJ; O'Connell RL; Banerjee S; Mileshkin L; Sykes P; Beale P; Fisher A; Bonaventura A; Millan D; Nottley S; Benson C; Hamilton A; Sjoquist K; Alexander L; Kelly C; Carty K; Divers L; Bradshaw N; Friedlander M;
Gynecol Oncol; 2021 Dec; 163(3):524-530. PubMed ID: 34625284
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903.
Mileshkin L; Edmondson R; O'Connell RL; Sjoquist KM; Andrews J; Jyothirmayi R; Beale P; Bonaventura T; Goh J; Hall M; Clamp A; Green J; Lord R; Amant F; Alexander L; Carty K; Paul J; Scurry J; Millan D; Nottley S; Friedlander M;
Gynecol Oncol; 2019 Jul; 154(1):29-37. PubMed ID: 31130288
[TBL] [Abstract][Full Text] [Related]
8. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum.
Gershenson DM; Sun CC; Iyer RB; Malpica AL; Kavanagh JJ; Bodurka DC; Schmeler K; Deavers M
Gynecol Oncol; 2012 Jun; 125(3):661-6. PubMed ID: 22406638
[TBL] [Abstract][Full Text] [Related]
9. The positivity of estrogen receptor and progesterone receptor may not be associated with metastasis and recurrence in epithelial ovarian cancer.
Chen S; Dai X; Gao Y; Shen F; Ding J; Chen Q
Sci Rep; 2017 Dec; 7(1):16922. PubMed ID: 29208958
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of anastrozole in women with asymptomatic müllerian cancer.
del Carmen MG; Fuller AF; Matulonis U; Horick NK; Goodman A; Duska LR; Penson R; Campos S; Roche M; Seiden MV
Gynecol Oncol; 2003 Dec; 91(3):596-602. PubMed ID: 14675683
[TBL] [Abstract][Full Text] [Related]
11. Endocrine treatment of high grade serous ovarian carcinoma; quantification of efficacy and identification of response predictors.
Stanley B; Hollis RL; Nunes H; Towler JD; Yan X; Rye T; Dawson C; Mackean MJ; Nussey F; Churchman M; Herrington CS; Gourley C
Gynecol Oncol; 2019 Feb; 152(2):278-285. PubMed ID: 30501904
[TBL] [Abstract][Full Text] [Related]
12. The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole.
George A; McLachlan J; Tunariu N; Della Pepa C; Migali C; Gore M; Kaye S; Banerjee S
BMC Cancer; 2017 Jun; 17(1):456. PubMed ID: 28666422
[TBL] [Abstract][Full Text] [Related]
13. Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma.
Llaurado Fernandez M; Dawson A; Kim H; Lam N; Russell H; Bruce M; Bittner M; Hoenisch J; Scott SA; Talhouk A; Chiu D; Provencher D; Nourmoussavi M; DiMattia G; Lee CH; Gilks CB; Köbel M; Carey MS
Gynecol Oncol; 2020 Apr; 157(1):12-20. PubMed ID: 31954537
[TBL] [Abstract][Full Text] [Related]
14. Quantification of ER/PR expression in ovarian low-grade serous carcinoma.
Escobar J; Klimowicz AC; Dean M; Chu P; Nation JG; Nelson GS; Ghatage P; Kalloger SE; Köbel M
Gynecol Oncol; 2013 Feb; 128(2):371-6. PubMed ID: 23103384
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer.
Secord AA; McCollum M; Davidson BA; Broadwater G; Squatrito R; Havrilesky LJ; Gabel AC; Starr MD; Brady JC; Nixon AB; Duska LR
Gynecol Oncol; 2019 Jun; 153(3):555-561. PubMed ID: 30929823
[TBL] [Abstract][Full Text] [Related]
16. Endocrine therapy in the management of low-grade serous ovarian/peritoneal carcinoma: Mounting evidence for therelative efficacy of tamoxifen and aromatase inhibitors.
Gershenson DM; Cobb LP; Sun CC
Gynecol Oncol; 2020 Dec; 159(3):601-603. PubMed ID: 33019983
[No Abstract] [Full Text] [Related]
17. Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network.
Sehouli J; Braicu EI; Richter R; Denkert C; Jank P; Jurmeister PS; Kunze CA; Budczies J; Darb-Esfahani S; Schmitt WD; Traut A; Grabowski J; Taube ET; Plett H
Hum Pathol; 2019 Mar; 85():299-308. PubMed ID: 30428389
[TBL] [Abstract][Full Text] [Related]
18. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
Gershenson DM; Sun CC; Bodurka D; Coleman RL; Lu KH; Sood AK; Deavers M; Malpica AL; Kavanagh JJ
Gynecol Oncol; 2009 Jul; 114(1):48-52. PubMed ID: 19361839
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer.
Argenta PA; Thomas SG; Judson PL; Downs LS; Geller MA; Carson LF; Jonson AL; Ghebre R
Gynecol Oncol; 2009 May; 113(2):205-9. PubMed ID: 19239974
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer.
Manning-Geist BL; Gordhandas SB; Giri DD; Iasonos A; Zhou Q; Girshman J; O'Cearbhaill RE; Zamarin D; Lichtman SM; Sabbatini PJ; Tew WP; Li K; McDonnell AS; Aviki EM; Chi DS; Aghajanian CA; Grisham RN
Gynecol Oncol; 2022 Jan; 164(1):12-17. PubMed ID: 34763937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
